Projected Earnings from the BioClonetics’ passive immunotherapy have been calculated by an independent national consulting firm. This analysis examines the expected potential profits from 2 perspectives: (1) considering sales only to North America and Western Europe and (2) considering sales to the major Markets including North America, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America. The potential earnings and underlying assumptions for application of our passive immunotherapy to major Markets are set forth here:
Potential Profit from Technology
A most appropriate market for the Company’s therapy includes the regions referred to as the “Major Markets”, including North American, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America wherein there are 10.6 million HIV positive individuals. Assuming a penetration rate of 1% rising to a maximum 15% over a five-year period, profit from making treatment available to these 10.6 million HIV positive individuals in the 7 major world markets would be $105 billion in the first 11 years.
The estimated earnings for this population group is shown below with the underlying assumptions presented below the graph.
Assumptions for passive immunotherapy predictive Earnings – 7 Major Markets
Major Markets – HIV population
North America, Western and Central Europe - 2.2 million
Eastern Europe and Central Asia – 1.4 million
South and Southeast Asia (including India) – 5.2 million
Latin America – 1.8 million
Total – 10.6 million
Assumes 10.6 million potential patient populations with HIV/AIDS
· Assumes 1.5% annual increase in potential population growth over the forecast period
· $8,000 treatment total cost per patient (single series of treatments for one year only)
· Assumes penetration of from 1% in year one to maximum of 15%
· Assumes a reduction in the population group by the number treated
Earnings/Graph – Passive Immunotherapy – Major Markets (North America, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America)
A vaccine against HIV has a much broader application and will produce significantly larger earnings.